Ardelyx, Inc.

ARDX

US0396971071

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 29/04/2024 BST			5-day change	1st Jan Change
6.46 ^USD	+0.62%		-0.77%	+4.19%

04-17	Wedbush Raises Price Target on Ardelyx to $14 From $13, Keeps Outperform Rating	MT
04-05	Leerink Partners Initiates Coverage on Ardelyx With Outperform Rating, $14 Price Target	MT

Ardelyx, Inc.(NasdaqGM:ARDX) dropped from S&P Biotechnology Select Industry Index

September 20, 2021 at 05:00 am

Latest news about Ardelyx, Inc.

Wedbush Raises Price Target on Ardelyx to $14 From $13, Keeps Outperform Rating	04-17	MT
Leerink Partners Initiates Coverage on Ardelyx With Outperform Rating, $14 Price Target	04-05	MT
Ardelyx, Inc. Announces the Appointment of Mike Kelliher as Executive Vice President, Corporate Development and Strategy	03-25	CI
Ardelyx Insider Sold Shares Worth $664,978, According to a Recent SEC Filing	03-22	MT
Ardelyx, Inc. announced that it has received $50 million in funding	03-04	CI
Sector Update: Health Care Stocks Mixed Premarket Friday	02-23	MT
Sector Update: Health Care	02-23	MT
Ardelyx's Q4 Swings to Loss; Revenues Down; Shares Down After-Hours	02-23	MT
Ardelyx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Transcript : Ardelyx, Inc., Q4 2023 Earnings Call, Feb 22, 2024	02-22
Ardelyx, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
Earnings Flash (ARDX) ARDELYX Posts Q4 Revenue $34.4M, vs. Street Est of $34.2M	02-22	MT
Sector Update: Health Care Stocks Slide Late Friday Afternoon	01-12	MT
Sector Update: Health Care	01-12	MT
Ardelyx's Xphozah to Attract 'Substantial Attention' in 2024, Wedbush Says	01-12	MT
Wedbush Adjusts Price Target on Ardelyx to $13 From $9, Maintains Outperform Rating	01-12	MT
Citigroup Raises Price Target on Ardelyx to $14 From $9, Maintains Buy Rating	01-10	MT
Raymond James Adjusts Ardelyx's Price Target to $15 From $12, Keeps Strong Buy Rating	01-09	MT
ARDELYX INC: JEFFERIES RAISES TARGET PRICE TO $11 FROM $8…	01-09	RE
Transcript : Ardelyx, Inc. - Special Call	01-08
Ardelyx Provides Update On 2024 Strategic Priorities	01-08	RE
Raymond James Initiates Ardelyx at Strong Buy Rating With $12 Price Target	12-18	MT
Ardelyx Insider Sold Shares Worth $253,925, According to a Recent SEC Filing	12-13	MT
Ardelyx Insider Sold Shares Worth $105,476, According to a Recent SEC Filing	12-08	MT
Ardelyx Announces Departure of Geoffrey Block as Board Member	11-13	CI

Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.

Sector

Biotechnology & Medical Research

Calendar

01/05/2024 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Ardelyx, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.46 USD

Average target price

13.39 USD

Spread / Average Target

+107.26%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ARDELYX, INC.	+4.19%	1.5B
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	102B
REGENERON PHARMACEUTICALS, INC.	+1.62%	96.29B
ARGENX SE	+1.46%	22.18B
BIONTECH SE	-16.67%	21.2B
GENMAB A/S	-8.58%	18.31B
WUXI APPTEC CO., LTD.	-38.74%	17.38B
BEIGENE, LTD.	-13.21%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.97B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs

Ardelyx, Inc.

Equities

ARDX

US0396971071

Biotechnology & Medical Research

Ardelyx, Inc.(NasdaqGM:ARDX) dropped from S&P Biotechnology Select Industry Index

Latest news about Ardelyx, Inc.

Chart Ardelyx, Inc.

Company Profile

Income Statement Evolution

Ratings for Ardelyx, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs